丹麦队列研究揭示黑色素瘤分期、复发与死亡中的性别差异
该研究基于丹麦癌症登记处2004—2022年确诊的30,497例黑色素瘤患者(男性14,409例,47%),中位随访8年,采用多因素logistic回归与竞争风险模型分析性别与分期、复发及死亡率的关系。结果显示男性确诊时分期更晚,且在校正分期后各期复发与黑色素瘤特异死亡率仍更高。
要点
- 男性确诊时Breslow厚度>4 mm、溃疡、淋巴结及远处转移风险均高于女性。
- 校正分期后,局限期男性复发和黑色素瘤特异死亡风险显著升高。
- 各分期男性预后均较差,提示早期发现与随访需考虑性别差异。
核心结论
- 男性确诊时黑色素瘤分期更晚,且按分期分层后复发与死亡风险仍高于女性。
- 研究提示早期检测、随访和治疗策略应考虑性别特异性方法。
研究设计与样本
- 丹麦全国基于人群的队列研究,纳入2004—2022年丹麦癌症登记处确诊的黑色素瘤患者。
- 共纳入30,497例患者,中位随访8年,其中男性14,409例(47%)。
- 采用多因素logistic回归分析确诊分期,采用竞争风险模型分析复发与死亡,并校正分期、合并症、年龄和日历年。
主要发现
- 男性Breslow厚度>4 mm的校正比值比为1.45(95%CI 1.31-1.59)。
- 男性溃疡存在的校正比值比为1.28(95%CI 1.18-1.39)。
- 男性>1个淋巴结转移的校正比值比为1.58(95%CI 1.38-1.80),远处转移为1.69(95%CI 1.48-1.94)。
- 局限期男性复发校正风险比为1.38(95%CI 1.27-1.51),黑色素瘤特异死亡为1.51(95%CI 1.34-1.71)。
- 局部区域期和转移期男性预后亦较差,但差异不如局限期显著。
临床怎么用
- 对男性黑色素瘤患者应加强早期发现与随访,以降低晚期确诊风险。
- 分期相同的男性患者复发和死亡风险更高,提示随访强度和治疗决策可考虑性别因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Male sex appears to be associated with more advanced melanoma stage and inferior prognosis, but population-based data on sex disparities in stage-specific recurrence and mortality remain limited. OBJECTIVES: The objective of this study was to examine sex disparities in (1) melanoma stage at diagnosis and (2) stage-specific recurrence and long-term melanoma-specific mortality. METHODS: This population-based cohort study included all Danes with melanoma from 2004 to 2022 identified in the Danish Cancer Register. The impact of sex on melanoma stage diagnosis (Breslow thickness, presence of ulceration, presence of lymph node metastases and presence of distant metastases) was investigated using multivariable logistic regression models. Furthermore, we examined melanoma recurrence, melanoma-specific and overall mortality for stage I + II (localized), stage III (locoregional) and stage IV (metastatic) melanoma in a competing risk model, adjusting for stage at diagnosis, comorbidity, age and calendar year. RESULTS: This study included 30,497 individuals diagnosed with melanoma; the median follow-up time was 8 years, and 14,409 (47%) were male. Males had, compared to females, an increased adjusted odds ratio (aOR) of Breslow thickness >4 mm (aOR 1.45, 95% CI: 1.31-1.59), presence of ulceration (aOR 1.28, 1.18-1.39), >1 lymph node metastases (aOR: 1.58, 1.38-1.80) and distant metastases (aOR: 1.69, 1.48-1.94). In stage-adjusted analyses, males with localized melanoma had an increased adjusted hazard ratio (aHR) of melanoma recurrence (aHR: 1.38, 1.27-1.51) and melanoma-specific mortality (aHR: 1.51, 1.34-1.71). In patients with locoregional and metastatic melanoma, males had an inferior prognosis, but it was less pronounced. CONCLUSIONS: This nationwide cohort study found that males were more likely to be diagnosed with more advanced stages of melanoma. Analyses stratified by stage at diagnosis, showed that males had a 20%-50% higher risk of melanoma recurrence, melanoma-specific and overall mortality across localized, locoregional and metastatic melanoma. UNLABELLED: WHAT IS THE DISEASE?: Melanoma is a form of skin cancer that develops from pigment‐producing cells in the skin. The number of people diagnosed with melanoma has been increasing worldwide. LOCATION OF THE STUDY: This study was carried out in Denmark using nationwide health registers. AIM OF THE STUDY: We wanted to find out if men and women differ in how advanced their melanoma is at diagnosis—such as if it has grown deeper into the skin or spread—and if their risks of recurrence or death vary by stage of the disease. METHODOLOGY: We included 30,497 people diagnosed with melanoma in Denmark between 2004 and 2022, with a median follow‐up of 8 years. We compared stage at diagnosis (tumour thickness, ulceration, spread to lymph nodes or distant metastases) as well as the risk of recurrence and death from melanoma between men and women. KEY FINDINGS: Men were more likely than women to be diagnosed with thicker tumours, ulceration, lymph node spread and distant metastases. Even when comparing men and women at the same melanoma stage, men had a 20%–50% higher risk of recurrence and death from melanoma. CONCLUSIONS AND PRACTICAL IMPLICATIONS: This study shows that men are at higher risk of advanced melanoma at diagnosis and worse outcomes across all stages. These findings highlight the need for sex‐specific approaches in early detection, follow‐up and treatment strategies, to improve prognosis and reduce the gap between men and women.
引用
- Lyngstrand JE, Røssell EL, Bønnelykke-Behrndtz ML, et al. Sex disparities in melanoma stage, recurrence and mortality: A Danish cohort study, 2004 to 2024. J Eur Acad Dermatol Venereol. 2025. PMID: 41277769. doi:10.1111/jdv.70180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。